Clinical trial · Interventional
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
A Prospective, Single-Center, Open-Label Exploratory Study of 68Ga-SorB PET/CT Imaging for the Diagnosis of Sortilin-Positive Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors. Eligible participants with confirmed or suspected melanoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, breast cancer, or ovarian cancer will undergo 68Ga-SorB PET/CT imaging. The imaging findings will be compared with standard-of-care 18F-FDG PET/CT, using pathology results and/or clinical follow-up as the reference standard. The primary objectives are to evaluate the safety and tolerability of 68Ga-SorB, assess imaging feasibility, and characterize tumor uptake using quantitative PET parameters, including SUVmax and tumor-to-background ratio (TBR). Secondary exploratory objectives include comparing lesion detection between 68Ga-SorB PET/CT and 18F-FDG PET/CT, assessing diagnostic sensitivity and specificity, evaluating imaging characteristics across different tumor types, and exploring the correlation between Sortilin expression and tracer uptake. This study will provide preliminary clinical evidence supporting the development of Sortilin-targeted molecular imaging and future theranostic applications.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Melanoma (Skin Cancer) | Melanoma | ONTOLOGY_EXACT | 0.85 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-SorB PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 68Ga-SorB PET/CT Imaging
- description
- Participants with suspected or confirmed malignant tumors will receive a single intravenous administration of 68Ga-SorB followed by PET/CT imaging. Imaging findings will be compared with clinically indicated 18F-FDG PET/CT performed within the predefined time window. No therapeutic intervention will be administered as part of this study.
- interventionNames
- Diagnostic Test: 68Ga-SorB PET/CT
Primary outcomes (3)
- measure
- Incidence of adverse events related to 68Ga-SorB PET/CT
- timeFrame
- From tracer administration until completion of the imaging visit (approximately 24 hours).
- description
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) related to administration of 68Ga-SorB, graded according to CTCAE.
- measure
- Successful completion of 68Ga-SorB PET/CT imaging
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * \- Adults aged 18 to 75 years. * Histologically confirmed or clinically suspected melanoma, hepatocellular carcinoma, lung cancer, breast cancer, pancreatic cancer, or ovarian cancer. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate hematologic, hepatic, renal, and coagulation function: * White blood cell count ≥ 4.0 × 10\^9/L or absolute neutrophil count ≥ 1.5 × 10\^9/L; * Platelet count ≥ 100 × 10\^9/L; * Hemoglobin ≥ 90 g/L; * PT or APTT ≤ 1.5 × upper limit of normal (ULN); * Total bilirubin ≤ 1.5 × ULN; * ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN for participants with liver metastases); * ALP ≤ 2.5 × ULN (or ≤ 4.5 × ULN for participants with bone or liver metastases); * Blood urea nitrogen and serum creatinine ≤ 1.5 × ULN. * Normal cardiac function. * Estimated life expectancy of at least 12 weeks. * Willing and able to comply with study procedures and follow-up. * At least one measurable target lesion according to RECIST version 1.1. * Participants of childbearing potential agree to use effective contraception during the study and for 3 months after PET/CT imaging. * Clinically indicated to undergo 18F-FDG PET/CT for tumor evaluation. * Able to understand the study procedures and provide written informed consent. Exclusion Criteria: * Pregnant or breastfeeding women. * Severe dysfunction of major organs (including heart, liver, or kidney) that, in the investigator's judgment, would make participation inappropriate. * Inability to tolerate PET/CT imaging or complete study follow-up. * Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
References
Publications (0)
Data not yet available